123IV · AI-ENABLED MEDTECH

AI-Enabled MedTech for Diagnostics, Surgery, and Infusion Care

Three platforms designed to remove unnecessary steps from clinical workflows.

No-Specimen Diagnostics Precision Surgical Oncology Autonomous Infusion Support

Explore the platforms Read the published study →

123-CY diagnostic device prototype with fingertip on the scan surface — **Diagnostics**Fingertip Raman + AI

Handheld and robotic surgical probe concepts — **Oncology**Detect → Treat → Confirm

Autonomous IV correction prototype mounted on an IV pole — **Infusion**Sense → Detect → Correct → Confirm

Clinical & Research Network

Weill Cornell MedicineClinical collaboration

Cornell UniversityEngineering collaboration

Dana-Farber / BrighamSurgical oncology support

Stevens Institute of TechnologyAutonomous infusion development

THREE PLATFORMS

One instinct, three applications

Every 123IV platform is built around the same idea: solve the clinical problem before it becomes a delay, an alarm, or an answer that arrives too late.

No-Specimen Diagnostics

Fingertip spectroscopy + AI

Rapid molecular information without blood, swabs, or specimen processing.

Explore the platform →

Precision Surgical Oncology

Raman + elastography + focal treatment

Detect → Treat → Confirm at the surgical margin in a single integrated workflow.

Explore the platform →

Autonomous Infusion

Closed-loop IV alarm mitigation

Correct common tubing interruptions before the alarm becomes the problem.

Explore the platform →

PLATFORM 01 · DIAGNOSTICS

Diagnosis, at the speed of light

A laser, a sensor, and a trained model replace the swab, the vial, and the wait.

PatientFingertip presented

→

IlluminateLow-power laser scan

→

Spectral signatureMolecular-level read

→

ML classificationTrained on clinical data

→

Result60-second acquisition

FIG. 1 — Signal path from optical acquisition through spectral processing and classification. No specimen is drawn, transported, or processed.

Working prototype · 123-CYReal hardware used for optical acquisition.

455patients enrolled

0.896AUROC

3clinical settings — ER, ICU, urgent care

60 secspectral acquisition used in the published study

Read the peer-reviewed manuscript →

PLATFORM 02 · SURGICAL ONCOLOGY

Detect. Treat. Confirm.

The optical platform extended for the precision a surgical margin demands.

DetectRaman + elastography margin scan

→

TreatFocal treatment at the margin

→

ConfirmRe-scan before closing

The platform is being developed as a multimodal intraoperative probe integrating Raman spectroscopy, shear-wave elastography, focal treatment, co-registration, and AI-guided interpretation in one workflow.

U.S. Patent12,702,304Intraoperative Probe for Cancer Diagnosis and Treatment · issued Aug. 11, 2026

Development and clinical support: Cornell engineering collaborators and surgical oncology collaborators at Dana-Farber / Brigham are supporting the program as it advances through engineering development toward future clinical evaluation.

Initial development is focused on a handheld platform, with laparoscopic and robotic versions planned.

Handheld and robotic-assisted surgical probe concepts — Handheld and robotic-assisted delivery concepts.

PLATFORM 03 · INFUSION

Correct the problem before the alarm becomes the problem

A closed-loop retrofit concept designed to work around the pump infrastructure hospitals already own.

First-generation autonomous IV correction prototype — Version 1 prototype · retrofit arm mounted on a standard IV pole.

Sense

→

Detect

→

Correct

→

Confirm

Built with Team A9 at Stevens Institute of Technology, the prototype explores mechanical detection and correction of common tubing failures before they escalate to an alarm.

The design uses sensing, controlled actuation, and verification rather than replacing the infusion pump itself.

SELECTED SHOWCASES

123IV in the clinical and engineering community

Recent presentations and prototype demonstrations across point-of-care diagnostics and autonomous infusion.

STEVENS INSTITUTE OF TECHNOLOGY

Autonomous IV System — Innovation Expo 2026

Five Stevens Institute of Technology Class of 2026 students, working with 123IV, developed and demonstrated an autonomous IV system using integrated sensing, real-time feedback control, and a robotic mechanism designed to detect and mechanically correct common IV tubing failures before they escalate into alarms. The team presented the system at the 2026 Stevens Innovation Expo. Stevens’ feature also notes that 123IV holds the patent for the autonomous IV infusion system and plans continued development toward commercialization.

Autonomous IV Infusion System project poster and prototype display at the Stevens Innovation Expo 2026

Stevens Innovation Expo 2026 — first-generation autonomous infusion prototype and project poster.

Featured by Stevens Institute of Technology · Innovation Expo · April 27, 2026

Read the Stevens feature →

CORNELL / WEILL CORNELL MEDICINE

PORTENT Point-of-Care Technology Showcase

123IV was selected to present its no-specimen, non-invasive diagnostic platform at the PORTENT Point-of-Care Technology Showcase at Weill Cornell Medicine on July 9, 2026. The showcase brought together clinicians, researchers, investors, industry partners, entrepreneurs, and innovators advancing point-of-care healthcare technologies.

123IV · PORTENT Point-of-Care Technology Showcase Weill Cornell Medicine · July 9, 2026

LEADERSHIP & ADVISORS

Clinical, engineering, and AI experience

Allen B. Chefitz, MD

Founder & CEO · Surgeon / Scientist

Led the design, build, and clinical validation of the no-specimen diagnostic device.

Elisa Long, MD

Chief Operating Officer

Leads company operations, partnership development, and study execution.

Gregg Vesonder, PhD

Advisor · Systems Engineering

Systems architecture, AI/ML integration, and scalable deployment.

Rohit Singh, PhD

Scientific Advisor

Machine learning and genomics; co-inventor of the no-specimen diagnostic platform.

Yongwu Yang, PhD

Optical Engineering

Raman spectroscopy and optical instrumentation.

Peter Szolovits, PhD

Scientific Advisor

MIT EECS and Clinical Decision-Making Group, MIT CSAIL.

INTELLECTUAL PROPERTY

A portfolio of protected inventions

Eight issued U.S. patents organized across the 123IV platforms, plus continuations, foreign filings, and pending applications.

No-Specimen Diagnostics

11,452,454 · Sep. 27, 2022

11,304,605 · Apr. 19, 2022

12,121,321 · Oct. 22, 2024

11,291,408 · Apr. 5, 2022

Precision Surgical Oncology

12,702,304 · Aug. 11, 2026

Intraoperative Probe for Cancer Diagnosis and Treatment

Autonomous Infusion

11,872,708 · Jan. 16, 2024

10,906,180 · Feb. 2, 2021

12,121,765 · Oct. 22, 2024

PARTNER WITH 123IV

Have a pilot site, a partnership, or a press question?

We welcome conversations with health systems, clinical investigators, engineering partners, strategic industry partners, and investors interested in advancing the 123IV platforms.

Email the team → abc@123IVrobot.com